Can a cannabis compound sharpen or dull the mind? a study puts CBG to the test
NCT ID NCT05324982
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial investigates how a single oral dose of cannabigerol (CBG), a natural compound from the cannabis plant, affects healthy adults. Over five sessions, participants receive either a placebo or one of four doses of CBG, then undergo eight hours of monitoring including blood and urine tests, heart rate and blood pressure checks, and computer-based tasks measuring attention, memory, and reaction speed. The goal is to understand CBG's safety, how the body processes it, and its short-term effects on the mind and body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an oral cannabis compound called cannabigerol (CBG)
- What this could lead to
- If successful, this study could provide the first detailed data on how CBG behaves in the human body, potentially guiding future research into its medical uses.
- What could go wrong
- This is a very early, small study in healthy volunteers, so results may not apply to people with medical conditions. The effects of CBG are still largely unknown, and it may cause side effects like other cannabis compounds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHAVIORAL PHARMACOLOGY OF CANNABIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Behavioral Pharmacology Research Unit
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.